Clinical Trial Update: 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating 4SCAR-T therapy targeting GD2, PSMA, and CD276 for neuroblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• 4SCAR-T therapy targeting GD2, PSMA and CD276

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: UNKNOWN